Kenvue Inc. (KVUE) EV/Sales Ratio: 2.81x
Is Kenvue Inc.’s EV/Sales ratio high or low?
Kenvue Inc.'s EV/Sales ratio of 2.81x is in line with its 3-year average of 3.05x, around the middle of its 3-year range (2.30x–3.76x).
As of Wednesday, June 24, 2026. 1.18% above its 12-month average of 2.78x.
KVUE EV/Sales Ratio Chart
KVUE Average EV/Sales Ratio Chart
KVUE Current vs Average EV/Sales Ratio Chart
KVUE EV/Sales Ratio Metrics
EV/SALES RATIO
2.81x
EV/SALES RATIO AVG TTM
2.78x
EV/SALES RATIO AVG 3Y
3.04x
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+1.18%
CURRENT VS 3Y AVG
-7.44%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
KVUE Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kenvue Inc. (KVUE) | $35.35B | 2.81x | 2.78x | 3.04x | N/A |
| Kimberly-Clark Corp (KMB)vs › | $35.43B | 2.55x | 2.46x | 2.58x | 2.63x |
| The Kroger Co. (KR)vs › | $35.17B | 0.39x | 0.44x | 0.40x | 0.39x |
| The Hershey Company (HSY)vs › | $36.36B | 3.43x | 3.79x | 3.89x | 4.40x |
| Archer-Daniels-Midland Company (ADM)vs › | $36.55B | 0.58x | 0.49x | 0.46x | 0.52x |
| Sysco Corporation (SYY)vs › | $37.91B | 0.62x | 0.63x | 0.63x | 0.71x |
| The Estée Lauder Companies Inc. (EL)vs › | $30.29B | 2.48x | 2.78x | 2.94x | 4.22x |
| Kellanova (K)vs › | $29.03B | 2.78x | 2.83x | 2.42x | 2.27x |
| Keurig Dr Pepper Inc. (KDP)vs › | $42.72B | 3.99x | 3.55x | 3.90x | 4.33x |
| The Kraft Heinz Company (KHC)vs › | $26.64B | 1.77x | 1.92x | 2.14x | 2.31x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Kenvue Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Kenvue Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Kenvue Inc. (KVUE)?
- The EV/Sales ratio for KVUE stock is 2.81x.
- Is Kenvue Inc.'s EV/Sales ratio high or low?
- Kenvue Inc.'s EV/Sales ratio of 2.81x is in line with its 3-year average of 3.05x, around the middle of its 3-year range (2.30x–3.76x).
- What is the TTM average EV/Sales ratio for Kenvue Inc. (KVUE)?
- The TTM average EV/Sales ratio for KVUE stock is 2.78x.
- What is the 3Y average EV/Sales ratio for Kenvue Inc. (KVUE)?
- The 3Y average EV/Sales ratio for KVUE stock is 3.04x.
Kenvue Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-23 | 2.81x |
| 2026-06-22 | 2.74x |
| 2026-06-18 | 2.77x |
| 2026-06-17 | 2.76x |
| 2026-06-16 | 2.81x |
| 2026-06-15 | 2.79x |
| 2026-06-12 | 2.78x |
| 2026-06-11 | 2.77x |
| 2026-06-10 | 2.76x |
| 2026-06-09 | 2.75x |
| 2026-06-08 | 2.70x |
| 2026-06-05 | 2.72x |
| 2026-06-04 | 2.62x |
| 2026-06-03 | 2.61x |
| 2026-06-02 | 2.67x |
| 2026-06-01 | 2.68x |
| 2026-05-29 | 2.67x |
| 2026-05-28 | 2.71x |
| 2026-05-27 | 2.72x |
| 2026-05-26 | 2.69x |
| 2026-05-22 | 2.70x |
| 2026-05-21 | 2.69x |
| 2026-05-20 | 2.67x |
| 2026-05-19 | 2.65x |
| 2026-05-18 | 2.66x |
| 2026-05-15 | 2.65x |
| 2026-05-14 | 2.66x |
| 2026-05-13 | 2.66x |
| 2026-05-12 | 2.69x |
| 2026-05-11 | 2.65x |
| 2026-05-08 | 2.71x |
| 2026-05-07 | 2.72x |
| 2026-05-06 | 2.74x |
| 2026-05-05 | 2.70x |
| 2026-05-04 | 2.67x |
| 2026-05-01 | 2.71x |
| 2026-04-30 | 2.72x |
| 2026-04-29 | 2.68x |
| 2026-04-28 | 2.72x |
| 2026-04-27 | 2.72x |
| 2026-04-24 | 2.71x |
| 2026-04-23 | 2.71x |
| 2026-04-22 | 2.69x |
| 2026-04-21 | 2.69x |
| 2026-04-20 | 2.73x |
| 2026-04-17 | 2.73x |
| 2026-04-16 | 2.71x |
| 2026-04-15 | 2.69x |
| 2026-04-14 | 2.70x |
| 2026-04-13 | 2.68x |
| 2026-04-10 | 2.70x |
| 2026-04-09 | 2.71x |
| 2026-04-08 | 2.69x |
| 2026-04-07 | 2.62x |
| 2026-04-06 | 2.69x |
| 2026-04-02 | 2.67x |
| 2026-04-01 | 2.70x |
| 2026-03-31 | 2.68x |
| 2026-03-30 | 2.68x |
| 2026-03-27 | 2.72x |
| 2026-03-26 | 2.72x |
| 2026-03-25 | 2.74x |
| 2026-03-24 | 2.72x |
| 2026-03-23 | 2.73x |
| 2026-03-20 | 2.70x |
| 2026-03-19 | 2.71x |
| 2026-03-18 | 2.72x |
| 2026-03-17 | 2.75x |
| 2026-03-16 | 2.74x |
| 2026-03-13 | 2.71x |
| 2026-03-12 | 2.70x |
| 2026-03-11 | 2.73x |
| 2026-03-10 | 2.77x |
| 2026-03-09 | 2.80x |
| 2026-03-06 | 2.83x |
| 2026-03-05 | 2.81x |
| 2026-03-04 | 2.80x |
| 2026-03-03 | 2.80x |
| 2026-03-02 | 2.89x |
| 2026-02-27 | 2.92x |
| 2026-02-26 | 2.91x |
| 2026-02-25 | 2.88x |
| 2026-02-24 | 2.91x |
| 2026-02-23 | 2.90x |
| 2026-02-20 | 2.87x |
| 2026-02-19 | 2.92x |
| 2026-02-18 | 2.95x |
| 2026-02-17 | 2.89x |
| 2026-02-13 | 2.93x |
| 2026-02-12 | 2.91x |
| 2026-02-11 | 2.91x |
| 2026-02-10 | 2.88x |
| 2026-02-09 | 2.86x |
| 2026-02-06 | 2.85x |
| 2026-02-05 | 2.85x |
| 2026-02-04 | 2.84x |
| 2026-02-03 | 2.79x |
| 2026-02-02 | 2.76x |
| 2026-01-30 | 2.76x |
| 2026-01-29 | 2.74x |
| 2026-01-28 | 2.75x |
| 2026-01-27 | 2.77x |
| 2026-01-26 | 2.79x |
| 2026-01-23 | 2.81x |
| 2026-01-22 | 2.81x |
| 2026-01-21 | 2.76x |
| 2026-01-20 | 2.79x |
| 2026-01-16 | 2.74x |
| 2026-01-15 | 2.74x |
| 2026-01-14 | 2.73x |
| 2026-01-13 | 2.71x |
| 2026-01-12 | 2.71x |
| 2026-01-09 | 2.69x |
| 2026-01-08 | 2.71x |
| 2026-01-07 | 2.68x |
| 2026-01-06 | 2.68x |
| 2026-01-05 | 2.69x |
| 2026-01-02 | 2.75x |
| 2025-12-31 | 2.74x |
| 2025-12-30 | 2.75x |
| 2025-12-29 | 2.73x |
| 2025-12-26 | 2.73x |
| 2025-12-24 | 2.74x |
| 2025-12-23 | 2.71x |
| 2025-12-22 | 2.71x |
| 2025-12-19 | 2.71x |
| 2025-12-18 | 2.72x |
| 2025-12-17 | 2.75x |
| 2025-12-16 | 2.74x |
| 2025-12-15 | 2.74x |
| 2025-12-12 | 2.75x |
| 2025-12-11 | 2.75x |
| 2025-12-10 | 2.75x |
| 2025-12-09 | 2.71x |
| 2025-12-08 | 2.68x |
| 2025-12-05 | 2.70x |
| 2025-12-04 | 2.71x |
| 2025-12-03 | 2.71x |
| 2025-12-02 | 2.69x |
| 2025-12-01 | 2.74x |
| 2025-11-28 | 2.75x |
| 2025-11-26 | 2.74x |
| 2025-11-25 | 2.71x |
| 2025-11-24 | 2.68x |
| 2025-11-21 | 2.66x |
| 2025-11-20 | 2.60x |
| 2025-11-19 | 2.59x |
| 2025-11-18 | 2.61x |
| 2025-11-17 | 2.61x |
| 2025-11-14 | 2.67x |
| 2025-11-13 | 2.68x |
| 2025-11-12 | 2.67x |
| 2025-11-11 | 2.67x |
| 2025-11-10 | 2.68x |
| 2025-11-07 | 2.69x |
| 2025-11-06 | 2.64x |
| 2025-11-05 | 2.61x |
| 2025-11-04 | 2.58x |
| 2025-11-03 | 2.60x |
| 2025-10-31 | 2.34x |
| 2025-10-30 | 2.32x |
| 2025-10-29 | 2.33x |
| 2025-10-28 | 2.35x |
| 2025-10-27 | 2.43x |
| 2025-10-24 | 2.42x |
| 2025-10-23 | 2.43x |
| 2025-10-22 | 2.44x |
| 2025-10-21 | 2.41x |
| 2025-10-20 | 2.41x |
| 2025-10-17 | 2.45x |
| 2025-10-16 | 2.30x |
| 2025-10-15 | 2.58x |
| 2025-10-14 | 2.56x |
| 2025-10-13 | 2.57x |
| 2025-10-10 | 2.63x |
| 2025-10-09 | 2.65x |
| 2025-10-08 | 2.55x |
| 2025-10-07 | 2.57x |
| 2025-10-06 | 2.50x |
| 2025-10-03 | 2.52x |
| 2025-10-02 | 2.51x |
| 2025-10-01 | 2.52x |
| 2025-09-30 | 2.57x |
| 2025-09-29 | 2.59x |
| 2025-09-26 | 2.60x |
| 2025-09-25 | 2.56x |
| 2025-09-24 | 2.65x |
| 2025-09-23 | 2.70x |
| 2025-09-22 | 2.67x |
| 2025-09-19 | 2.84x |
| 2025-09-18 | 2.81x |
| 2025-09-17 | 2.84x |
| 2025-09-16 | 2.81x |
| 2025-09-15 | 2.83x |
| 2025-09-12 | 2.92x |
| 2025-09-11 | 2.91x |
| 2025-09-10 | 2.86x |
| 2025-09-09 | 2.91x |
| 2025-09-08 | 2.85x |
| 2025-09-05 | 2.88x |
| 2025-09-04 | 3.12x |
| 2025-09-03 | 3.11x |
| 2025-09-02 | 3.15x |
| 2025-08-29 | 3.14x |
| 2025-08-28 | 3.12x |
| 2025-08-27 | 3.15x |
| 2025-08-26 | 3.15x |
| 2025-08-25 | 3.20x |
| 2025-08-22 | 3.26x |
| 2025-08-21 | 3.24x |
| 2025-08-20 | 3.26x |
| 2025-08-19 | 3.24x |
| 2025-08-18 | 3.19x |
| 2025-08-15 | 3.20x |
| 2025-08-14 | 3.19x |
| 2025-08-13 | 3.27x |
| 2025-08-12 | 3.29x |
| 2025-08-11 | 3.21x |
| 2025-08-08 | 3.22x |
| 2025-08-07 | 3.28x |
| 2025-08-06 | 3.21x |
| 2025-08-05 | 3.23x |
| 2025-08-04 | 3.30x |
| 2025-08-01 | 3.23x |
| 2025-07-31 | 3.21x |
| 2025-07-30 | 3.24x |
| 2025-07-29 | 3.30x |
| 2025-07-28 | 3.32x |
| 2025-07-25 | 3.38x |
| 2025-07-24 | 3.34x |
| 2025-07-23 | 3.35x |
| 2025-07-22 | 3.36x |
| 2025-07-21 | 3.29x |
| 2025-07-18 | 3.28x |
| 2025-07-17 | 3.26x |
| 2025-07-16 | 3.26x |
| 2025-07-15 | 3.20x |
| 2025-07-14 | 3.25x |
| 2025-07-11 | 3.19x |
| 2025-07-10 | 3.14x |
| 2025-07-09 | 3.12x |
| 2025-07-08 | 3.11x |
| 2025-07-07 | 3.14x |
| 2025-07-03 | 3.16x |
| 2025-07-02 | 3.14x |
| 2025-07-01 | 3.15x |
| 2025-06-30 | 3.14x |
| 2025-06-27 | 3.14x |
| 2025-06-26 | 3.17x |
| 2025-06-25 | 3.17x |
| 2025-06-24 | 3.18x |
| 2025-06-23 | 3.20x |
| 2025-06-20 | 3.20x |
| 2025-06-18 | 3.20x |
| 2025-06-17 | 3.21x |
| 2025-06-16 | 3.23x |
| 2025-06-13 | 3.21x |
| 2025-06-12 | 3.28x |
| 2025-06-11 | 3.26x |
| 2025-06-10 | 3.22x |
Showing the most recent 260 of 786 data points. The chart above shows the full history.
Related Metrics
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry